Shots:
- MAIA Biotechnology has reported P-II (THIO-101) trial data assessing ateganosine followed by Libtayo (cemiplimab) in pts with advanced NSCLC who progressed after ≥2 SoC therapy regimens
- As of Jun 30, 2025, ateganosine (180mg) showed mPFS of 5.6 vs 2.5mos. & mOS of 17.8mos., plus 2 pts completed 33 cycles across pts of all treatment lines, suggesting potential for extended dosing; data presented at WCLC’25
- Ateganosine (THIO, 6-thio-dG) is a telomere-targeting agent in development for NSCLC, with the P-II (THIO-101) expansion trial enrolling pts since Jul 2025
Ref: MAIA Biotechnology | Image: MAIA Biotechnology | Press Release
Related News:- Nanjing Leads Biolabs Reports First Patient Enrolment in P-Ib/II Trial of Opatisumab for Advanced Melanoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
